View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
February 25, 1987

DEC GIVES HELPING HAND TO DRUG CAD FIRM POLYGEN

By CBR Staff Writer

Polgen Corp, the Waltham, Massachusetts start-up that is developing computer-aided design software that will enable pharmacuticals companies to cut the time it takes to create new designer drugs, has signed an co-operative development agreement with DEC that will enable it to package up its software with DEC VAX workstations under VMS. The decision to approach DEC was a logical one, because Polygen is now run by a 17-year DEC veteran, Joel Schwartz (CI No 494). Under the agreement, Polygen will develop a scientific research automation software system which will be integrated with the workstations and VMS, and DEC will provide Polygen with technical development assistance and prototypes of forthcoming personal graphics workstations. The low-cost DEC workstations and the Polygen research automation software are expected to be ready by the end of the year. The aim of the collaboration is to enable pharmaceutical and chemical companies using the new DEC stations to improve productivity of researchers, technicians, managers and clerical staff involved in analysis, production, and distribution of scientific documentation.

Topics in this article :
Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
THANK YOU